1de Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross- sectional worldwide study [ J ]. Lancet Oncol, 2010, ll ( ll ) : 1048 - 1056.
2Castellsague X, Diaz M, de Sanjose S,et al. Worldwide human papillo- mavirns etiology of cervical adenocarcinoma and its cofaetors : implica- tions for screening and prevention [ J]. J Natl Cancer Inst,2006,98 (5) :303 -315.
3Ferlay J,Soerjomataram I,Ervik M,el al. GLOBOCAN 2012 vl. O, Cancer incidence and mortality worldwide :IARC CancerBase No. 11 [ EB ]. Lyon, France: International Agency for Research on Cancer,2013. Available at : http ://globocan. iarc. fr. (Accessed on June 25,2014).
4Pimenta JM, Galindo C, Jenkins D, et al. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic hu- man papillomavirns vaccination [ J ]. BMC Cancer, 2013, 13 (11) :553.
5Molijn A, Jenkins D, Chen W, et al. The complex relationship between human papillomavirns and cervical adenocarcinomal J 1. Int J Cancer, 2016,138(2) :409 -416.
